TRACON Pharmaceuticals (NASDAQ:TCON) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a report released on Tuesday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Stock Performance

Shares of NASDAQ TCON opened at $0.04 on Tuesday. TRACON Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $14.75. The stock’s 50-day simple moving average is $0.09 and its 200-day simple moving average is $0.67. The firm has a market cap of $119,350.00, a price-to-earnings ratio of 0.01 and a beta of 1.43.

TRACON Pharmaceuticals (NASDAQ:TCON) last announced its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter. The business had revenue of $0.06 million during the quarter.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.